Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semglee vs Lantus Extension in T1DM
NCT02666430Phase 3Completed
- Sponsor
- Mylan
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Mylan. Primary endpoint: Change in Hemoglobin A1c at 36 weeks. Started Dec 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02666430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666430.